S&P 500   3,246.87 (-1.47%)
DOW   28,554.00 (-1.50%)
QQQ   218.15 (-2.04%)
AAPL   308.55 (-3.07%)
FB   214.61 (-1.53%)
MSFT   162.35 (-1.63%)
GOOGL   1,425.35 (-2.78%)
AMZN   1,831.16 (-1.64%)
CGC   22.25 (-1.77%)
BABA   204.80 (-4.19%)
MU   55.16 (-4.50%)
GE   11.52 (-1.71%)
TSLA   545.75 (-3.38%)
AMD   48.96 (-2.76%)
T   38.40 (-0.26%)
ACB   1.95 (-2.01%)
NFLX   342.64 (-2.98%)
BAC   32.87 (-2.00%)
DIS   136.02 (-2.90%)
GILD   63.34 (+0.30%)
S&P 500   3,246.87 (-1.47%)
DOW   28,554.00 (-1.50%)
QQQ   218.15 (-2.04%)
AAPL   308.55 (-3.07%)
FB   214.61 (-1.53%)
MSFT   162.35 (-1.63%)
GOOGL   1,425.35 (-2.78%)
AMZN   1,831.16 (-1.64%)
CGC   22.25 (-1.77%)
BABA   204.80 (-4.19%)
MU   55.16 (-4.50%)
GE   11.52 (-1.71%)
TSLA   545.75 (-3.38%)
AMD   48.96 (-2.76%)
T   38.40 (-0.26%)
ACB   1.95 (-2.01%)
NFLX   342.64 (-2.98%)
BAC   32.87 (-2.00%)
DIS   136.02 (-2.90%)
GILD   63.34 (+0.30%)
S&P 500   3,246.87 (-1.47%)
DOW   28,554.00 (-1.50%)
QQQ   218.15 (-2.04%)
AAPL   308.55 (-3.07%)
FB   214.61 (-1.53%)
MSFT   162.35 (-1.63%)
GOOGL   1,425.35 (-2.78%)
AMZN   1,831.16 (-1.64%)
CGC   22.25 (-1.77%)
BABA   204.80 (-4.19%)
MU   55.16 (-4.50%)
GE   11.52 (-1.71%)
TSLA   545.75 (-3.38%)
AMD   48.96 (-2.76%)
T   38.40 (-0.26%)
ACB   1.95 (-2.01%)
NFLX   342.64 (-2.98%)
BAC   32.87 (-2.00%)
DIS   136.02 (-2.90%)
GILD   63.34 (+0.30%)
S&P 500   3,246.87 (-1.47%)
DOW   28,554.00 (-1.50%)
QQQ   218.15 (-2.04%)
AAPL   308.55 (-3.07%)
FB   214.61 (-1.53%)
MSFT   162.35 (-1.63%)
GOOGL   1,425.35 (-2.78%)
AMZN   1,831.16 (-1.64%)
CGC   22.25 (-1.77%)
BABA   204.80 (-4.19%)
MU   55.16 (-4.50%)
GE   11.52 (-1.71%)
TSLA   545.75 (-3.38%)
AMD   48.96 (-2.76%)
T   38.40 (-0.26%)
ACB   1.95 (-2.01%)
NFLX   342.64 (-2.98%)
BAC   32.87 (-2.00%)
DIS   136.02 (-2.90%)
GILD   63.34 (+0.30%)
Log in

TSE:ASP - Acerus Pharmaceuticals Stock Price, Forecast & News

Today's Range N/A
50-Day Range
C$0.06
MA: C$0.07
C$0.08
52-Week Range N/A
Volume90,500 shs
Average Volume81,773 shs
Market CapitalizationC$20.90 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone416-679-0771

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$5.32 million
Book ValueC($0.03) per share

Profitability

Miscellaneous

Employees29
Market CapC$20.90 million
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable

Receive ASP News and Ratings via Email

Sign-up to receive the latest news and ratings for ASP and its competitors with MarketBeat's FREE daily newsletter.


Acerus Pharmaceuticals (TSE:ASP) Frequently Asked Questions

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ASP."

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (TSE:ASP) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.02) earnings per share for the quarter. The business had revenue of ($0.22) million for the quarter. View Acerus Pharmaceuticals' Earnings History.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Acerus Pharmaceuticals.

Has Acerus Pharmaceuticals been receiving favorable news coverage?

News coverage about ASP stock has been trending somewhat negative recently, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Acerus Pharmaceuticals earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Acerus Pharmaceuticals.

Who are some of Acerus Pharmaceuticals' key competitors?

What other stocks do shareholders of Acerus Pharmaceuticals own?

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the folowing people:
  • Dr. Nathan Bryson, Chief Scientific Officer
  • Mr. Philippe Savard, VP, Gen. Counsel & Corp. Sec.
  • Mr. Edward Gudaitis, Pres , CEO & Director
  • Mr. Robert M. Motz, Chief Financial Officer
  • Mr. Hubert Tomasz Czerwinski, Pres of Acerus Pharmaceuticals SRL

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

How big of a company is Acerus Pharmaceuticals?

Acerus Pharmaceuticals has a market capitalization of C$0.00 and generates C$5.32 million in revenue each year. Acerus Pharmaceuticals employs 29 workers across the globe.View Additional Information About Acerus Pharmaceuticals.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is http://www.aceruspharma.com/.

How can I contact Acerus Pharmaceuticals?

The company can be reached via phone at 416-679-0771.


MarketBeat Community Rating for Acerus Pharmaceuticals (TSE ASP)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about Acerus Pharmaceuticals and other stocks. Vote "Outperform" if you believe ASP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel